17 dicembre 2007 / 13:32 / tra 10 anni

C.R. Bard to license hernia repair product from Genzyme

Dec 17 (Reuters) - Medical-device maker C.R. Bard Inc (BCR.N) said it entered into a license deal with biotech firm Genzyme Corp GENZ.O to make and market the Sepramesh hernia repair product line and incorporate a related coating technology into future hernia repair applications.

A unit of Bard will begin marketing the line immediately, the company said in a statement. Details of the agreement were not disclosed. (Reporting by Avishek Mishra in Bangalore; Editing by Pratish Narayanan)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below